The Caring for Carcinoid Foundation is pleased to announce two research grants awarded through a partnership with the American Association for Cancer Research (AACR). Both of these grants, each awarding of $250,000 over two years, will allow investigators to explore new, targeted strategies for treating neuroendocrine cancer patients.
"CFCF's partnership with AACR is a critical component of our strategy to achieve a cure. To succeed, we believe it will take top scientists to achieve an understanding of neuroendocrine tumors at their basic scientific level. Partnering with AACR, one of the premier research associations in the country, will enable CFCF to attract some of the nation's most talented scientists to carcinoid and neuroendocrine cancer research. I am also grateful to our research partners, the Raymond and Beverly Sackler Fund for the Arts and Sciences, for their generous funding of two additional fellowships to attract young investigators to the field. The future is exciting for carcinoid and related neuroendocrine cancer research." - CFCF Founder Nancy Lindholm
Oncolytic Viral Therapy for Neuroendocrine Cancers
Charles Rudin, M.D., Ph.D., Johns Hopkins University
This innovative project will study the only anti-cancer virus with selective affinity for neuroendocrine tumor cells and define the population of neuroendocrine patients most likely to respond to the Seneca Valley Virus.
Suppression of Neuroendocrine Tumors Via Epigenetic Regulation
Xianxin Hua, M.D., Ph.D., the University of Pennsylvania
By targeting the pathway regulated by menin, a tumor suppressor that is mutated in patients with inherited Multiple Endocrine Neoplasia Type I (MEN1) syndrome, Dr. Hua's study seeks to uncover a novel treatment strategy for patients with neuroendocrine tumors.
Please click here for the press release issued by the AACR.